Accelerating Cell & Gene Therapy Manufacturing Through High-Impact CDMO Partnerships In mRNA, Neoantigen & Personalised Vaccine Development
9:40 am - Thursday 1st October 2026
- Reduce early development risk with early, structured CDMO engagement and shorten timelines for mRNA, neoantigen and personalized cancer vaccine programs in cell & gene therapy pipelines
- Aligning process development and CMC expectations between biopharma and CDMOs to avoid scale-up failures and enable smoother translation from preclinical to commercial supply
- Defining effective partnership models for complex modalities, including tech transfer best practices, capacity planning, and managing variability in patient-specific manufacturing workflows
